6,120
0.00%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hyundai Pharmaceutical Co
Its shares trade on KRX under the ticker 004310.KS. It has been listed since 28 June 1978. In the fiscal year to 30 November 2025, it reported revenue of ₩191.79bn and net income of ₩2.52bn. At that date it held total assets of ₩163.22bn and shareholders' equity of ₩82.10bn.
Hyundai Pharmaceutical Co., Ltd. engages in the manufacturing and distribution of pharmaceutical products, health food drinks and medical equipment. The company is headquartered in Cheonan, Chungcheongnam-Do. The firm mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. The company also provides dietary various beverages and medical equipment. The firm mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Jun 1978
- Employees
- 383
- Website
- hyundaipharm.co.kr ↗
Leadership
Pay as last reported
- Mr. Han Gu LeeChairman, since 2018
- Mr. Sang Jun LeePresident, Chief Executive Officer, Director
- Mr. Yi Sun HwangVice President
- Mr. Seong Heon KimVice President
- Mr. Byeong Chun LeeVice President
- Mr. Chi Yong KimManaging Director
- Mr. Sang Hwan HwangManaging Director
- Mr. Jae Hun LeeManaging Director
- Mr. Ju Hwan LeeManaging Director
- Mr. Min Gyu LeeManaging Director
- Ms. Sin Suk RyuManaging Director
- Mr. Taek Sang WooManaging Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hyundai Pharmaceutical employs 383 full-time employees in Cheonan, South Korea.
- The company manufactures ophthalmological tablets and clopidogrel bisulfate for hypertension treatment.
- Hyundai Pharmaceutical distributes pharmaceuticals and health food products domestically within South Korea.
Weaknesses
- Hyundai Pharmaceutical focuses solely on the domestic South Korean market for product distribution.
- The company's product range includes only ophthalmological tablets and clopidogrel bisulfate.
- Hyundai Pharmaceutical's leasing business is a minor part of its overall operations.
Opportunities
- Hyundai Pharmaceutical could expand its distribution of vitamin products to international markets.
- The company may increase sales of calcium supplements in the domestic South Korean market.
- Hyundai Pharmaceutical can develop new medical equipment for global healthcare needs.
Threats
- Hyundai Pharmaceutical faces competition from other South Korean pharmaceutical companies in the domestic market.
- The company must comply with strict South Korean pharmaceutical regulations.
- Hyundai Pharmaceutical's reliance on the domestic market poses a risk if local demand decreases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.